{
    "rcn": "209460",
    "acronym": "PREFER",
    "topics": "IMI2-2015-05-01",
    "title": "Patient Preferences in benefit risk assessments during the drug life cycle",
    "startDate": "01/10/2016",
    "endDate": "30/09/2021",
    "objective": "The PREFER project will deliver an overview and evaluation of preference elicitation methods to be applied in the entire drug life cycle, i.e. in the early stages of identifying medical needs, in clinical testing, to guide decisions on reimbursement and to make decisions on withdrawal of drugs from the market. A broad array of (combinations of) patient preference methods will be tested prospectively in a large number of case studies. The availability of large patient cohorts will enable to test new methods or deviations from existing methods in a randomized manner, by comparing well-known methods with newer ones. The use of simulation studies will both contribute to smarter design of case studies and to exploring the sensitivity of outcomes of preference studies. Based on discussions with a broad representation of stakeholders e.g. patients, patient organisations, regulatory authorities, HTA bodies and reimbursement agencies, suitable methods will be tested and their contributions to improved decision making will be discussed in recommendations adapted to the needs of all relevant stakeholders.  The recommendations from PREFER are expected to lead to changed practices, in that industry will routinely assess whether a preference study would add value at key decision points in the medicinal product life cycle and, if so, implement patient-preference elicitation studies according to the PREFER project recommendations. The PREFER consortium consist of 16 industry partners and 17 academic and SME members including representation from academia, patient organizations, HTA bodies, reimbursement agencies, and project management.",
    "totalCost": "12000001",
    "ecMaxContribution": "6000000",
    "coordinator": "UPPSALA UNIVERSITET",
    "coordinatorCountry": "SE",
    "participants": "\"INSTITUTO TUMORI \"\"GIOVANNI PAOLO II\"\"\";Pfizer Ltd;MindBytes;Federaal Kenniscentrum voor de Gezondheidszorg / Centre fÈdÈral díexpertise des soins de santÈ;ISTITUTO EUROPEO DI ONCOLOGIA SRL;AbbVie Ltd;NOVARTIS PHARMA AG;Merck Sharp and Dohme, Corp.;ASTRAZENECA AB;THE UNIVERSITY OF BIRMINGHAM;UNIVERSITY OF NEWCASTLE UPON TYNE;F. HOFFMANN-LA ROCHE AG;CSL Behring GmbH;Takeda Development Centre Europe Ltd.;UNIVERSITAIR MEDISCH CENTRUM UTRECHT;FORUM EUROPEEN DES PATIENTS (FPE);Astellas Pharma Europe BV;Actelion Pharmaceuticals Ltd;EUROPEAN CANCER PATIENT COALITION;Amgen;BAYER AKTIENGESELLSCHAFT;ERASMUS UNIVERSITEIT ROTTERDAM;ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM;SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT;UNIVERSITATSKLINIKUM ERLANGEN;KATHOLIEKE UNIVERSITEIT LEUVEN;Eli Lilly and Company Ltd;International Alliance of Patients' Organizations;Steinbeiﬂer Project Management;Muscular Dystrophy UK;JANSSEN PHARMACEUTICA NV;Merck KGaA",
    "participantCountries": "IT;UK;BE;CH;US;SE;DE;NL;LU;FR",
    "projectParticipants": {
        "917706040": {
            "orgId": "917706040",
            "orgName": "Steinbeißer Project Management",
            "ecContrib": 262500
        },
        "999969703": {
            "orgId": "999969703",
            "orgName": "ISTITUTO EUROPEO DI ONCOLOGIA SRL",
            "ecContrib": 335000
        },
        "999915189": {
            "orgId": "999915189",
            "orgName": "UNIVERSITAIR MEDISCH CENTRUM UTRECHT",
            "ecContrib": 618672
        },
        "999839335": {
            "orgId": "999839335",
            "orgName": "ERASMUS UNIVERSITEIT ROTTERDAM",
            "ecContrib": 551125
        },
        "999941379": {
            "orgId": "999941379",
            "orgName": "ASTRAZENECA AB",
            "ecContrib": 0
        },
        "997585928": {
            "orgId": "997585928",
            "orgName": "Eli Lilly and Company Ltd",
            "ecContrib": 0
        },
        "999907526": {
            "orgId": "999907526",
            "orgName": "THE UNIVERSITY OF BIRMINGHAM",
            "ecContrib": 238750
        },
        "999985029": {
            "orgId": "999985029",
            "orgName": "UPPSALA UNIVERSITET",
            "ecContrib": 1566849
        },
        "999988424": {
            "orgId": "999988424",
            "orgName": "ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM",
            "ecContrib": 67575
        },
        "998928893": {
            "orgId": "998928893",
            "orgName": "FORUM EUROPEEN DES PATIENTS (FPE)",
            "ecContrib": 65000
        },
        "999812466": {
            "orgId": "999812466",
            "orgName": "Actelion Pharmaceuticals Ltd",
            "ecContrib": 0
        },
        "988316026": {
            "orgId": "988316026",
            "orgName": "\"INSTITUTO TUMORI \"\"GIOVANNI PAOLO II\"\"\"",
            "ecContrib": 233275
        },
        "999965241": {
            "orgId": "999965241",
            "orgName": "MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN",
            "ecContrib": 0
        },
        "950126835": {
            "orgId": "950126835",
            "orgName": "Amgen",
            "ecContrib": 0
        },
        "999601782": {
            "orgId": "999601782",
            "orgName": "F. HOFFMANN-LA ROCHE AG",
            "ecContrib": 0
        },
        "940741115": {
            "orgId": "940741115",
            "orgName": "International Alliance of Patients' Organizations",
            "ecContrib": 63173
        },
        "919995628": {
            "orgId": "919995628",
            "orgName": "CSL Behring GmbH",
            "ecContrib": 0
        },
        "998198095": {
            "orgId": "998198095",
            "orgName": "SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT",
            "ecContrib": 0
        },
        "954843557": {
            "orgId": "954843557",
            "orgName": "Federaal Kenniscentrum voor de Gezondheidszorg / Centre fédéral d’expertise des soins de santé",
            "ecContrib": 252500
        },
        "999866495": {
            "orgId": "999866495",
            "orgName": "UNIVERSITATSKLINIKUM ERLANGEN",
            "ecContrib": 233722
        },
        "984108263": {
            "orgId": "984108263",
            "orgName": "EUROPEAN CANCER PATIENT COALITION",
            "ecContrib": 223250
        },
        "922258444": {
            "orgId": "922258444",
            "orgName": "MindBytes",
            "ecContrib": 259937
        },
        "999991334": {
            "orgId": "999991334",
            "orgName": "KATHOLIEKE UNIVERSITEIT LEUVEN",
            "ecContrib": 683750
        },
        "999985417": {
            "orgId": "999985417",
            "orgName": "UNIVERSITY OF NEWCASTLE UPON TYNE",
            "ecContrib": 264922
        },
        "922250005": {
            "orgId": "922250005",
            "orgName": "Muscular Dystrophy UK",
            "ecContrib": 80000
        },
        "927359189": {
            "orgId": "927359189",
            "orgName": "AbbVie Ltd",
            "ecContrib": 0
        },
        "994154068": {
            "orgId": "994154068",
            "orgName": "Astellas Pharma Europe BV",
            "ecContrib": 0
        }
    },
    "calculatedTotalContribution": 6000000
}